Abstract: A display apparatus includes a backlight module, a panel module, and a plurality of double-sided adhesive tapes. The backlight module includes a bezel. The frame has a supporting surface. The panel module includes a glass substrate and a plurality of chips. The glass substrate is disposed on the supporting surface. An edge of the glass substrate has a bonding region. The chips are disposed at the bonding region. The chips and the supporting surface are respectively located at two opposite sides of the glass substrate. The double-sided adhesive tapes are disposed between the supporting surface and the bonding region. Each of the double-sided adhesive tapes is aligned with a gap between two adjacent chips.

Abstract: The present invention provides compounds of Formula (I): their use as H3 antagonists/inverse agonists, processes for their preparation, and pharmaceuticals compositions thereof.

Abstract: A compound of formula (I) as well as pharmaceutically acceptable salt thereof, wherein R1 to R10, A, Q, X and Y are as defined in the specification and claims, and their use as a pharmaceutical for the treatment or prophylaxis of respiratory syncytial virus disease.

Abstract: A power module includes a first power chip and a second power chip, each of which has at least two electrodes. The power module is applied to a power converter having a power density higher than 15 W/inch3 and a maximum efficiency higher than 92%, or to a power converter having a power density higher than 20 W/inch3 or having a maximum efficiency higher than 93%. At least one of the power chips operates at a frequency higher than 25 kHz.

Abstract: To be precisely extracted a house footprint. There is provided a geospatial information creating system for extracting a footprint of a house from an aerial photograph, comprising a processor for executing a program, a memory for storing data required for executing the program, and a storage unit for storing the aerial photograph. The processor detects edges of an image based on a characteristic quantity of neighboring pixels in the aerial photograph stored in the storage unit; extracts an orientation of the house by analyzing directions of the detected edges; and generates a polygon of an outline of the house by using linear lines of the extracted orientation of the house.

Abstract: New compounds are disclosed for multimerizing immunophilins and proteins containing immunophilin or immunophilin-related domains. The compounds are of the formula M-L-Q where M is a synthetic ligand for an FKBP protein.

Abstract: A seal is provided for preventing axial leakage through a radial gap between a stationary structure and a rotating structure. The radial gap is defined by an inner radial surface opposing an outer radial surface across the radial gap. The seal includes at least one land disposed on one of the inner radial surface and outer radial surface. At least one first tooth and at least one second tooth project from the other of the radial surfaces. The second tooth is shorter than the first tooth. At least one of the first tooth and second tooth, is configured to extend at an angle upstream. This angle is defined between a radial surface from which the first or second tooth projects and an upstream surface of the same tooth. The angle is less than or equal to about 80 degrees.

Abstract: A method of determining a steam quality of a wet steam located in an interior of a steam turbine includes emitting from an optical probe a plurality of wavelengths through the wet steam, measuring with the optical probe a wet steam intensity corresponding to each of the plurality of wavelengths emitted through the wet steam, determining an intensity ratio vector by dividing the wet steam intensity by a corresponding dry steam intensity for each of the plurality of wavelengths, successively applying scaling factors to the intensity ratio vector to obtain a scaled intensity ratio vector, calculating a suitable value for each of the scaling factors to obtain a plurality of residuals, determining a minimum residual of the plurality of residuals, determining a droplet size distribution by calculating the droplet number density corresponding to the minimum residual, and determining the steam quality based on the droplet size distribution.

Abstract: A mouse assembly used for a computer includes a first mouse module and a second mouse module. The first mouse module includes a first connector, and the second mouse module includes a second connector. The second mouse module is detachably and electrically connected to the first mouse module through the first connector and the second connector. When the first connector is mechanically and electrically connected to the second connector, the first mouse module and the second mouse module are assembled together, and the mouse assembly is used as a wireless mouse. When the first connector is mechanically disconnected from the second connector, the first mouse module intercommunicates with the second mouse module, and the mouse assembly is used as touch input device.

Abstract: A map generation system comprising: a mobile device for acquiring location data of a vehicle and a status of the vehicle at a time of acquisition of the location; and a server for processing the acquired location data of the vehicle. The server comprises an input interface, a first storage unit, a processor and a second storage unit. The server includes a management unit for collecting a plurality of pieces of the track data obtained by a motion of the vehicle, an extraction unit for extracting feature points of the plurality of pieces of the track data on a road from which the plurality of pieces of the track data are collected to calculate a Spline curve satisfying the extracted feature points, and an update unit for adding the calculated Spline curve as a lane central line to the digital road map to update map data.

Abstract: Disclosed are compounds of the formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein W is a bond, —C(?S)—, —S(O)—, —S(O)2—, —C(?O)—, —O—, —C(R6)(R7)—, —N(R5)— or —C(?N(R5))—; X is —O—, —N(R5)— or —C(R6)(R7)—; provided that when X is —O—, U is not —O—, —S(O)—, —S(O)2—, —C(?O)— or —C(?NR5)—; U is a bond, —S(O)—, —S(O)2—, —C(O)—, —O—, —P(O)(OR15)—, —C(?NR5)—, —(C(R6)(R7))b— or —N(R5)—; wherein b is 1 or 2; provided that when W is —S(O)—, —S(O)2—, —O—, or —N(R5)—, U is not —S(O)—, —S(O)2—, —O—, or —N(R5)—; provided that when X is —N(R5)— and W is —S(O)—, —S(O)2—, —O—, or —N(R5)—, then U is not a bond; and R1, R2, R3, R4, R5, R6, and R7 are as defined in the specification; and pharmaceutical compositions comprising the compounds of formula I.

Abstract: Disclosed are compounds of the formula or a pharmaceutically acceptable salt or solvate thereof, wherein R1 is R is —C(O)—N(R27)(R28) or and the remaining variables are as defined in the specification. Also disclosed are pharmaceutical compositions comprising the compounds of formula I. Also disclosed are methods of treating cognitive or neurodegenerative diseases such as Alzheimer's disease. Also disclosed are pharmaceutical compositions and methods of treating cognitive or neurodegenerative diseases comprising the compounds of formula I in combination with a ?-secretase inhibitor other than those of formula I, an HMG-CoA reductase inhibitor, a gamma-secretase inhibitor, a non-steroidal anti-inflammatory agent, an N-methyl-D-aspartate receptor antagonist, a cholinesterase inhibitor or an anti-amyloid antibody.

Abstract: Disclosed are compounds of the formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein each variable in Formula 1 are as defined in the specification; and pharmaceutical compositions comprising the compounds of formula I. Also disclosed are methods of inhibiting aspartyl protease, and in particular, the methods of treating cardiovascular diseases, cognitive and neurodegenerative diseases, and the methods of inhibiting of Human Immunodeficiency Virus, plasmepins, cathepsin D and protozoal enzymes. Also disclosed are methods of treating cognitive or neurodegenerative diseases using the compounds of formula I in combination with a cholinesterase inhibitor or a muscarinic m1 agonist or m2 antagonist.

Abstract: Disclosed are compounds of the formula or a pharmaceutically acceptable salt or solvate thereof, wherein R1 is R is —C(O)—N(R27)(R28) or and the remaining variables are as defined in the specification. Also disclosed are pharmaceutical compositions comprising the compounds of formula I. Also disclosed are methods of treating cognitive or neurodegenerative diseases such as Alzheimer's disease. Also disclosed are pharmaceutical compositions and methods of treating cognitive or neurodegenerative diseases comprising the compounds of formula I in combination with a ?-secretase inhibitor other than those of formula I, an HMG-CoA reductase inhibitor, a gamma-secretase inhibitor, a non-steroidal anti-inflammatory agent, an N-methyl-D-aspartate receptor antagonist, a cholinesterase inhibitor or an anti-amyloid antibody.

Abstract: Disclosed are compounds of the formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein each variable in Formula 1 are as defined in the specification; and pharmaceutical compositions comprising the compounds of formula I. Also disclosed are methods of inhibiting aspartyl protease, and in particular, the methods of treating cardiovascular diseases, cognitive and neurodegenerative diseases, and the methods of inhibiting of Human Immunodeficiency Virus, plasmepins, cathepsin D and protozoal enzymes. Also disclosed are methods of treating cognitive or neurodegenerative diseases using the compounds of formula I in combination with a cholinesterase inhibitor or a muscarinic m1 agonist or m2 antagonist.

Abstract: Disclosed are compounds of the formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein each variable in Formula 1 are as defined in the specification; and pharmaceutical compositions comprising the compounds of formula I. Also disclosed are methods of inhibiting aspartyl protease, and in particular, the methods of treating cardiovascular diseases, cognitive and neurodegenerative diseases, and the methods of inhibiting of Human Immunodeficiency Virus, plasmepins, cathepsin D and protozoal enzymes. Also disclosed are methods of treating cognitive or neurodegenerative diseases using the compounds of formula I in combination with a cholinesterase inhibitor or a muscarinic m1 agonist or m2 antagonist.

Abstract: Disclosed are compounds of the formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein W is a bond, —C(?S)—, —S(O)—, —S(O)2—, —C(?O)—, —O—, —C(R6)(R7)—, —N(R5)— or —C(?N(R5))—; X is —O—, —N(R5)— or —C(R6)(R7)—; provided that when X is —O—, U is not —O—, —S(O)—, —S(O)2—, —C(?O)— or —C(?NR5)—; U is a bond, —S(O)—, —S(O)2—, —C(O)—, —O—, —P(O)(OR15)—, —C(?NR5)—, —(C(R6)(R7))b— or —N(R5)—; wherein b is 1 or 2; provided that when W is —S(O)—, —S(O)2—, —O—, or —N(R5)—, U is not —S(O)—, —S(O)2—, —O—, or —N(R5)—; provided that when X is —N(R5)— and W is —S(O)—, —S(O)2—, —O—, or —N(R5)—, then U is not a bond; and R1, R2, R3, R4, R5, R6, and R7 are as defined in the specification; and pharmaceutical compositions comprising the compounds of formula I.

Abstract: The present invention provides a compound of formula I or II or a pharmaceutically acceptable salt form thereof, wherein R1, R2, R3, R4, R5, A1, A2, A3, A4, and A5, are as defined herein. The compounds of formula I or II have ALK and/or c-Met inhibitory activity, and may be used to treat proliferative disorders.

Abstract: New compounds are disclosed for multimerizing immunophilins and proteins containing immunophilin or immunophilin-related domains. The compounds are of the formula M-L-Q where M is a synthetic ligand for an FKBP protein.

Abstract: A method of determining a steam quality of a wet steam located in an interior of a steam turbine includes emitting from an optical probe a plurality of wavelengths through the wet steam, measuring with the optical probe a wet steam intensity corresponding to each of the plurality of wavelengths emitted through the wet steam, determining an intensity ratio vector by dividing the wet steam intensity by a corresponding dry steam intensity for each of the plurality of wavelengths, successively applying scaling factors to the intensity ratio vector to obtain a scaled intensity ratio vector, calculating a suitable value for each of the scaling factors to obtain a plurality of residuals, determining a minimum residual of the plurality of residuals, determining a droplet size distribution by calculating the droplet number density corresponding to the minimum residual, and determining the steam quality based on the droplet size distribution.